CASI Pharmaceuticals (FRA:ENM) ROCE %: 0.00% (As of Dec. 2025)

What is CASI Pharmaceuticals ROCE %?

CASI Pharmaceuticals FRA:ENM 29 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CASI Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

CASI Pharmaceuticals (FRA:ENM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CASI Pharmaceuticals ROCE % Related Terms

CASI Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals ROCE % Chart

CASI Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-29.80

-38.03

-37.51

-101.31

0.00

CASI Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															-176.98	-339.24	-8,370.04	0.00	0.00

29GF Score

CASI Pharmaceuticals Inc FRA:ENM

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CASI Pharmaceuticals ROCE % Calculation

CASI Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-38.456	/	( ( (51.259 - 34.812)	+	(21.905 - 42.418) )	/ 2 )
	=	-38.456	/	( (16.447	+	-20.513)	/ 2 )
	=	-38.456	/	-2.033
	=	1,891.59 %

CASI Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	-43.836	/	( ( (20.842 - 33.587)	+	(21.905 - 42.418) )	/ 2 )
	=	-43.836	/	( ( -12.745	+	-20.513 )	/ 2 )
	=	-43.836	/	-16.629
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 0.00% mean?

CASI Pharmaceuticals (FRA:ENM) has a ROCE % of 0.00% as of Dec. 2025.

Is CASI Pharmaceuticals' ROCE % too high?

CASI Pharmaceuticals' current ROCE % is 0.00%. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does CASI Pharmaceuticals' ROCE % compare to ITRMF and OGEN?

CASI Pharmaceuticals' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. CASI Pharmaceuticals's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CASI Pharmaceuticals stock overvalued right now?

CASI Pharmaceuticals (FRA:ENM) has a current ROCE % of 0.00%. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current ROCE % is 0.00%. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.

Key valuation signals for FRA:ENM:

ROCE %: 0.00%
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ITRMF OGEN AZTR VRAX BBLG SLXN VIVS PKTX CDT CLDI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CASIF:USA

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025

Website https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.

29GF Score

Get the complete analysis for FRA:ENM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54

Price

€11.74

GF Value

View FRA:ENM Analysis

See ROCE % data for all stocks →